Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful...
Quarter
HOUSTON--(BUSINESS WIRE)--Nov 30, 2020-- Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND ®...